USFDA finds several violations in Aurobindo sterile injections unit

FDA investigators have observed violations in sterilisation process to prevent microbial contamination and shortcomings in facility management procedures along with lapses in the design of the manufacturing plant. The same unit had come under the FDA radar in March 2018.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35q7HWh
via IFTTT